Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Thursday, April 18, 2024

update : E-esperance (TMA zapping ) 'probiotic' and TMA breathalyzer (via FSU IGEM team 2023 and 24)

E-esperance and Florida State University IGEM 2024 update (IGEM competition is in Nov24) :

Had a chat with 2 members of the FSU IGEM 2024 team. 
the 2 main news stories are :

E-esperance TMA-zapping probiotic project is continuing as a sort of IGEM FSU "team of 23 pre-company" project at FSU. 
Most of the 23 team have left but 2 are still working on this as a post-IGEM pre-company thing (curently based at FSU ?) to hopefully become a private company. 
The 2 from the 2024 team I talked to dont know much as it's not their project. Looks like it will be a liquid you take maybe 3 times a day and decide the dose etc.
This is how the conversation is recalled (could be wrong).

This years FSU IGEM 24 team's project is likely to be... a TMA breathalyzer sensor.
I guess probably will be like the Foodmarble Aire but to detect Trimethylamine.  
This is for the November IGEM comp, so I guess they are at the early stages. Maybe subject to change.
TMAU / FMO3 Malodor sufferers tend to be unable to smell themselves, and neither can family (due to genetics ?) and some others (? carriers ?), so a device to monitor is a necessity really. 
The idea is to maybe use it in tandem with E-esperance. 
use device on waking.
set dose of E-esperance (it's a liquid).
They said wait 2 hours to eat meal (it's early days).
And maybe take e.g. 3 doses a day.
The IGEM 23 team wiki suggested it would cost maybe $10 a week, but this couldn't be confirmed in the chat.

So the 24 team are working on a TMA-breathalyzer device for the November 2024 IGEM comp.
The 24 team aren't working on E-esperance (that's a separate project). I guess long-term the 2 might become 1 project.

Hopefully these 2 projects will result in :
E-esperance TMA-zapper liquid probiotic.
a TMA Breathalyzer      

No update on e-esperance was available. the 2 from the 24 team said they aren't updated much either, but may have an update in a few months. Don't think its been tried on humans yet. A I recall the concept was proven (in a dish) for the 23 IGEM conference.
E-esperance seems to be based on 3 enzymes very good at metabolizing TMA which are genetically inserted into benign E-coli bacteria, to be taken like a TMA-specific probiotic (if you want to think of it as a probiotic).

all known info on E-esperance is from the FSU IGEM 23 comp pages (which was also updated after the event).
Fantastic info that covers everything about it (until last update).

These 2 projects would seem the "best" possible projects for TMAU/FMO3 Malodor 
(aside from FMO3 gene therapy in humans, which medium term is probably likely from the clinical sector).

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization

Saturday, April 13, 2024

Unveiling the Breath: Propylene Oxide as a Diagnostic Marker

In the past 15 years, MEBO Research has been at the forefront of unraveling the mysteries behind TMAU and related undiagnosed conditions not yet accepted by medical establishment. Our journey began with blood tests and challenge tests like the choline and glucose challenge, aimed at understanding gut fermentation profiles. Over time, we discovered the link between various types of MEBO and PATM and the microbiome. 
While malodorous skin bacteria in the gut were a common factor, we also uncovered many variations and subtle imbalances contributing to TMAU-like or PATM perception.

Our ultimate goal was to avoid challenge tests, leading us to also explore urine metabolomics. Collaborating with Dr. Wishart, we found that while challenging, it's possible to detect malodor signatures in fasting morning urine breath. However, the influence of diet posed a significant challenge, resulting in numerous subtypes.

In 2012-2013, in collaboration with Dr. Phillips and Menssana Research, we started the Breath Metabolomics study. We hypothesized that breath metabolites would hold signatures for conditions like Trimethylaminuria (TMAU) and TMAU-like conditions such as PATM. Our findings revealed significant differences, particularly in the detoxification of environmental compounds.

Our new paper posted on MedRxiv reports some of the results from the Breath Metabolomics study, emphasizing compounds associated with oxidative stress and environmental toxins like Propylene Oxide. These compounds have proven effective in distinguishing individuals who have never tested positive for TMAU from those who have. Could this mark a turning point in our efforts to comprehend and tackle undiagnosed malodor conditions?

PAPER: Irene S. Gabashvili 2024 Propylene Oxide in Exhaled Breath as a Marker for Discriminating TMAU-like Conditions from TMAU medRxiv 2024.04.11.24305677; doi:

Clinical Trial: NCT03451994


get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization

Monday, January 29, 2024

Living with MEBO

In the recent study by Cole and Drs. Shephard, Phillips and Janmohamed, in collaboration with our MEBO Research, the emotional landscape of living with MEBO/TMAU is laid bare, revealing a world where individuals are often met with misunderstanding and social exclusion. The respondents, all navigating the challenges of TMAU in the UK, shared heart-wrenching experiences of bullying, ostracism, and a profound lack of empathy from others. The workplace (36 respondents, 90%) and social settings (35 respondents, 88%), places where support and acceptance should thrive, turned out to be the most common arenas for these painful encounters. This societal blindness to their struggle not only amplifies their emotional burden but also deepens their sense of isolation. The survey uncovers a poignant truth: living with TMAU is not just a physical battle but a relentless emotional ordeal, marked by a constant struggle for acceptance and understanding.

The emotional turmoil doesn't end there. The study highlights a critical dilemma – to disclose or not to disclose their condition. For many, this decision is a double-edged sword. Revealing their condition might bring some level of understanding, yet it also risks further stigma and exclusion. This uncertainty breeds a unique kind of loneliness and stress, where the fear of judgment constantly weighs against the hope for empathy. The findings underscore a desperate need for a shift in societal perception and support structures. It's clear that these individuals are not just battling a metabolic disorder but are also fighting for their place in a society that often overlooks the invisible hardships they endure daily. The call for greater awareness and mental health support resonates through each response, painting a picture of a community in urgent need of empathy and a deeper understanding of their struggles.


Flaherty CC, Phillips IR, Janmohamed A, Shephard EA. Living with trimethylaminuria and body and breath malodour: personal perspectives. BMC Public Health. 2024 Jan 18;24(1):222. doi: 10.1186/s12889-024-17685-w. PMID: 38238734; PMCID: PMC10797923.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization